Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:KIN

Kindred Biosciences (KIN) Stock Price, News & Analysis

Kindred Biosciences logo

About Kindred Biosciences Stock (NASDAQ:KIN)

Advanced Chart

Key Stats

Today's Range
$9.24
$9.26
50-Day Range
$9.08
$9.25
52-Week Range
$3.46
$9.28
Volume
178,496 shs
Average Volume
840,890 shs
Market Capitalization
$420.52 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive KIN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kindred Biosciences and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

KIN Stock News Headlines

America Betrayed
Porter Stansberry says he got one thing wrong—and now millions of Americans could pay the price. After warning about a dangerous flaw in America’s financial system for 15 years, he believed Trump might fix it. Instead, he says the problem has only grown worse. In his new emergency broadcast, Breaking Point, Porter reveals why this flaw may now be irreversible—and how it could gut retirement accounts, trigger mass wealth destruction, and blindside hard-working investors.tc pixel
Kindred Hospital East Greensboro
Japan's Sony terminates $10 bln Zee India merger
European Shares Edge Higher With ECB Meeting In The Spotlight
Earnings Optimism May Contribute To Continued Strength On Wall Street
See More Headlines

KIN Stock Analysis - Frequently Asked Questions

Kindred Biosciences, Inc. (NASDAQ:KIN) released its quarterly earnings data on Thursday, August, 5th. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by $0.04. The biopharmaceutical company earned $3.54 million during the quarter, compared to analysts' expectations of $8.12 million. Kindred Biosciences had a negative net margin of 529.26% and a negative trailing twelve-month return on equity of 54.19%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Kindred Biosciences investors own include CorMedix (CRMD), Sorrento Therapeutics (SRNE), Micron Technology (MU), bluebird bio (BLUE), Novavax (NVAX), Bristol Myers Squibb (BMY) and Meta Platforms (META).

Company Calendar

Last Earnings
8/05/2021
Today
9/02/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:KIN
CIK
1561743
Fax
N/A
Employees
63
Year Founded
2013

Profitability

EPS (Trailing Twelve Months)
($0.55)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$21.80 million
Net Margins
-529.26%
Pretax Margin
N/A
Return on Equity
-54.19%
Return on Assets
-39.76%

Debt

Debt-to-Equity Ratio
0.19
Current Ratio
7.02
Quick Ratio
7.02

Sales & Book Value

Annual Sales
$42.16 million
Price / Sales
9.97
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.75 per share
Price / Book
5.29

Miscellaneous

Outstanding Shares
45,462,000
Free Float
N/A
Market Cap
$420.52 million
Optionable
Optionable
Beta
1.30

Social Links

Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

This page (NASDAQ:KIN) was last updated on 9/2/2025 by MarketBeat.com Staff
From Our Partners